Multicenter Transplant Alliance is a research consortium focusing on kidney (MTA-K) and pancreas (MTA-P) transplantation outcomes.
MTA is the only freestanding clinical trials consortium in transplantation.
MTA is comprised of 13 leading medical institutions in the United States.
MTA-k and MTA-p perform more than 10% and 20% of kidney and pancreas transplants, respectively, in the United States each year.
For more information about being part of a clinical trial or to collaborate with the consortia, please contact us.
We are an ongoing multicenter research consortium addressing specific problems in kidney & pancreas transplant patients across the United States.
We are willing and able to explore new therapy and employ novel adaptive trial design methodology for transplant patients.
We use adaptive trial design methodology which is both cost-effective and safer than conventional methodology.
We conduct research with professional- ism and a high regard for patient safety, confidentiality, transparency and truth.
The major advantage of our group is that improving outcomes of kidney transplant recipients can be performed with greater efficiency, quality, and innovation than ever before. more details
Facilitating innovative clinical and translational research in pancreas transplant recipients through partnership between like-minded clinical centers, researchers, industry, and funding agencies. more details